Semax evidence check
Semax improves focus in humans.
Verdict
Mostly Animal Evidence with an evidence grade of D. The sources found for this starter review were animal or mechanistic studies, not strong evidence that Semax improves focus in healthy humans.
What this means
This grade applies only to the claim on this page, including the stated population and outcome. A supported claim in one context should not be stretched into a broader peptide promise.
What this does not mean
This page is not dosing guidance, a protocol, a recommendation to buy or use a product, or personal medical advice. High-risk claims need narrow wording, source links, and human review before publication.
Source trail
Evidence is listed by source type so you can see whether the claim rests on labeling, human studies, preclinical work, anecdotes, or vendor language.
Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain.
Rat mechanistic source for Semax and BDNF signaling; indirect for human focus claims.
Open sourceSemax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.
Rat behavioral/neurochemical source; not direct evidence of improved focus in humans.
Open sourceDisclosure
Disclosure: Some links may be affiliate links. Peptide Fact Checks may earn a commission if you use them. That does not affect evidence grades, verdicts, or vendor transparency notes.